The ArteSense product is based on a technology that has been
applied for a long time. This technology involves
the use of alloplastic material as a permanent injectable for cosmetic
applications. The alloplastic material in the product product consists of
biocompatible fixed particles of polymethylmethacrylate (PMMA) of a
defined size (32-40 µm) and with a completely round and smooth surface.
The fixed particles are suspended in atelocollagen so as to make injection
possible. Another advantage of using atelocollagen is the degradation
speed in the body, which gives the body time to encapsulate the fixed
particles and to station them securely for permanent cosmetic results.
Although ArteSense basically uses identical substances, the
composition of the product has been innovated in such a way that it has
obtained an original value, justifying a pending patent. The innovation
consists of the fixed particles being covered by a layer of a resorbable
albuminous substance with a coarse surface.
The principle advantages include; degradation speed of atelocollagen
being manipulated (i.e. slowed down), so that the fixed particles are less
likely to migrate and/or accumulate after they have been injected into the
body (They are suspended more securely in the atelocollagen matrix), and
the effect of the treatment remains constant over a longer period of time
(due to larger overlapping of degrading atelocollagen and substances
produced by the body itself).
ArteSense, Aphrodite Gold and ArteColl are based on the same technology, are
used in similar application areas and consist of the same basic substances
known for their long history of safe and effective use in medical
applications. The current available clinical data of the mentioned basic
materials as well as the ArteColl product are therefore the appropriate
sources of clinical information. However, additional clinical evaluation
will be conducted in order to found the above improvements of ArteSense in relation to ArteColl.
